Axsome Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Axsome Therapeutics, Inc. on June 22, 2023. The report discloses a material change in the company's independent registered public accounting firm.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the change of auditors and does not contain financial statement data.
Material Changes
- Appointment of New Auditor: The Audit Committee approved the engagement of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, effective June 30, 2023.
- Dismissal of Previous Auditor: Ernst & Young LLP was dismissed as the independent registered public accounting firm, effective June 30, 2023.
- Audit History: Reports issued by Ernst & Young for the fiscal years ended December 31, 2022, and 2021, were unqualified and contained no adverse opinions, disclaimers, or modifications regarding uncertainty, audit scope, or accounting principles.
- Disagreements: There were no disagreements between the Company and Ernst & Young on accounting principles, practices, or auditing scope during the relevant periods.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors beyond the standard disclosure regarding the auditor change. The company confirmed that no consultations occurred with Deloitte regarding accounting principles or audit opinions prior to the engagement.
Key Facts for Investor Verification
- Verify the effective date of the auditor transition (June 30, 2023) and the start of Deloitte's engagement.
- Confirm that the dismissal of Ernst & Young was not due to any disagreements on accounting or auditing matters.
- Review the attached letter from Ernst & Young (Exhibit 16.1) to ensure it aligns with the company's disclosures.
- Note that this filing does not impact the company's financial results for the period but changes the entity responsible for future audits.